# **PFIZER INC**

ISIN: US7170811035 WKN: 717081103 Asset Class: Stock

E-mail: -



#### **Company Profile**

10001-2192 New York

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

# Financial figures, Fiscal year: from 01.01. to 31.12.

	202	23	20	22	20:	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	43,333,000,000		51,259,000,000		59,693,000,000	
Common stock capital		478,000,000		476,000,000		473,000,000
Fixed assets	183,168,000,000		145,946,000,000		121,783,000,000	
Equity capital of a company		89,288,000,000		95,917,000,000		77,463,000,000
Cash and cash equivalents	2,853,000,000		416,000,000		1,944,000,000	
Accrued liabilities		11,364,000,000		12,062,000,000		15,055,000,000
Other assets	-		-		-	
Current liabilities		47,794,000,000		42,138,000,000		42,671,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		89,419,000,000		59,150,000,000		61,342,000,000
Different income		-		-		-
Other liabilities		13,251,000,000		10,584,000,000		7,233,000,000
Total assets	226,501,000,000	226,501,000,000	197,205,000,000	197,205,000,000	181,476,000,000	181,476,000,000

# **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	88,000	83,000	79,000
Equity ratio	39.54%	48.77%	42.83%
Debt-equity ratio	152.90%	105.05%	133.48%

### **Others**

	2023	2022	2021
Tax Expense Rate	-105.29%	9.58%	7.62%

# **PFIZER INC**

ISIN: US7170811035 WKN: 717081103 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	58,496,000,000	100,330,000,000	81,288,000,000
Net income	2,133,000,000	31,366,000,000	22,415,000,000
EBIT	1,670,659,800	33,209,344,000	23,789,528,400
Operating income before taxes	1,058,000,000	34,729,000,000	24,311,000,000
Cash Flow	8,700,000,000	33,227,000,000	32,580,000,000
Net interest income	-745,000,000	-1,111,000,000	-1,363,000,000
Research and development expenses	10,578,000,000	11,426,000,000	13,828,000,000
Income taxes	-1,114,000,000	3,328,000,000	1,852,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	615,936	1,120,070	953,436

# **Board of Directors**

Members of Management Board		
D 177		
Dan Littman	Member of Board of Directors	
Helen Hobbs	Member of Board of Directors	
Scott Gottlieb	Member of Board of Directors	
Susan Desmond-Hellmann	Member of Board of Directors	
Susan Hockfield	Member of Board of Directors	
James Quincey	Member of Board of Directors	
James Smith	Member of Board of Directors	
Joseph Echevarria	Member of Board of Directors	
Ronald Blaylock	Member of Board of Directors	
Shantanu Narayen	Member of Board of Directors	
Suzanne Johnson	Member of Board of Directors	
Albert Bourla	Chairman of Managing Board	
Aamir Malik	Member of Executive Committee	
Alexandre de Germay	Member of Executive Committee	
Chris Boshoff	Member of Executive Committee	
Dave Denton	Member of Executive Committee	
Douglas M. Lankler	Member of Executive Committee	
Lidia Fonseca	Member of Executive Committee	
Mikael Dolsten	Member of Executive Committee	
Mike McDermott	Member of Executive Committee	
Payal Sahni Becher	Member of Executive Committee	
Rady A. Johnson	Member of Executive Committee	
Sally Susman	Member of Executive Committee	